Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

546 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion.
Aldea M, Marinello A, Duruisseaux M, Zrafi W, Conci N, Massa G, Metro G, Monnet I, Gomez Iranzo P, Tabbo F, Bria E, Guisier F, Vasseur D, Lindsay CR, Ponce-Aix S, Cousin S, Citarella F, Fallet V, Minatta JN, Eisert A, de Saint Basile H, Audigier-Valette C, Mezquita L, Calles A, Mountzios G, Tagliamento M, Remon Masip J, Raimbourg J, Terrisse S, Russo A, Cortinovis D, Rochigneux P, Pinato DJ, Cortellini A, Leonce C, Gazzah A, Ghigna MR, Ferrara R, Dall'Olio FG, Passiglia F, Ludovini V, Barlesi F, Felip E, Planchard D, Besse B. Aldea M, et al. Among authors: felip e. J Thorac Oncol. 2023 May;18(5):576-586. doi: 10.1016/j.jtho.2022.12.018. Epub 2023 Jan 13. J Thorac Oncol. 2023. PMID: 36646211 Free article.
A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy.
Felip E, Rojo F, Reck M, Heller A, Klughammer B, Sala G, Cedres S, Peralta S, Maacke H, Foernzler D, Parera M, Möcks J, Saura C, Gatzemeier U, Baselga J. Felip E, et al. Clin Cancer Res. 2008 Jun 15;14(12):3867-74. doi: 10.1158/1078-0432.CCR-07-5186. Clin Cancer Res. 2008. PMID: 18559607 Clinical Trial.
Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.
Mazières J, Peters S, Lepage B, Cortot AB, Barlesi F, Beau-Faller M, Besse B, Blons H, Mansuet-Lupo A, Urban T, Moro-Sibilot D, Dansin E, Chouaid C, Wislez M, Diebold J, Felip E, Rouquette I, Milia JD, Gautschi O. Mazières J, et al. Among authors: felip e. J Clin Oncol. 2013 Jun 1;31(16):1997-2003. doi: 10.1200/JCO.2012.45.6095. Epub 2013 Apr 22. J Clin Oncol. 2013. PMID: 23610105
An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer.
Scagliotti GV, Felip E, Besse B, von Pawel J, Mellemgaard A, Reck M, Bosquee L, Chouaid C, Lianes-Barragán P, Paul EM, Ruiz-Soto R, Sigal E, Ottesen LH, Lechevalier T. Scagliotti GV, et al. Among authors: felip e. J Thorac Oncol. 2013 Dec;8(12):1529-37. doi: 10.1097/JTO.0000000000000005. J Thorac Oncol. 2013. PMID: 24389434 Free article. Clinical Trial.
Lungscape: resected non-small-cell lung cancer outcome by clinical and pathological parameters.
Peters S, Weder W, Dafni U, Kerr KM, Bubendorf L, Meldgaard P, O'Byrne KJ, Wrona A, Vansteenkiste J, Felip E, Marchetti A, Savic S, Lu S, Smit E, Dingemans AM, Blackhall FH, Baas P, Camps C, Rosell R, Stahel RA; ETOP Lungscape Investigators. Peters S, et al. Among authors: felip e. J Thorac Oncol. 2014 Nov;9(11):1675-84. doi: 10.1097/JTO.0000000000000320. J Thorac Oncol. 2014. PMID: 25436801 Free article.
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.
Jänne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, Haggstrom D, Felip E, Kim JH, Frewer P, Cantarini M, Brown KH, Dickinson PA, Ghiorghiu S, Ranson M. Jänne PA, et al. Among authors: felip e. N Engl J Med. 2015 Apr 30;372(18):1689-99. doi: 10.1056/NEJMoa1411817. N Engl J Med. 2015. PMID: 25923549 Free article. Clinical Trial.
Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study.
Vansteenkiste JF, Canon JL, De Braud F, Grossi F, De Pas T, Gray JE, Su WC, Felip E, Yoshioka H, Gridelli C, Dy GK, Thongprasert S, Reck M, Aimone P, Vidam GA, Roussou P, Wang YA, Di Tomaso E, Soria JC. Vansteenkiste JF, et al. Among authors: felip e. J Thorac Oncol. 2015 Sep;10(9):1319-1327. doi: 10.1097/JTO.0000000000000607. J Thorac Oncol. 2015. PMID: 26098748 Free PMC article. Clinical Trial.
Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC.
Vergnenegre A, Massuti B, de Marinis F, Carcereny E, Felip E, Do P, Sanchez JM, Paz-Arez L, Chouaid C, Rosell R; Spanish Lung Cancer Group, Italian Association of Thoracic Oncology, and French Lung Cancer Group. Vergnenegre A, et al. Among authors: felip e. J Thorac Oncol. 2016 Jun;11(6):801-7. doi: 10.1016/j.jtho.2016.02.004. Epub 2016 Feb 18. J Thorac Oncol. 2016. PMID: 26899757 Free article. Clinical Trial.
The Evolving Role of Nivolumab in Non-Small-Cell Lung Cancer for Second-Line Treatment: A New Cornerstone for Our Treatment Algorithms. Results From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology.
Gridelli C, Besse B, Brahmer JR, Crinò L, Felip E, de Marinis F. Gridelli C, et al. Among authors: felip e. Clin Lung Cancer. 2016 May;17(3):161-8. doi: 10.1016/j.cllc.2016.01.004. Epub 2016 Jan 28. Clin Lung Cancer. 2016. PMID: 26908078 Review.
546 results